190 related articles for article (PubMed ID: 20464378)
21. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S
Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
[TBL] [Abstract][Full Text] [Related]
22. Strontium ranelate: a look back at its use for osteoporosis.
Reginster JY; Neuprez A
Expert Opin Pharmacother; 2010 Dec; 11(17):2915-27. PubMed ID: 21050035
[TBL] [Abstract][Full Text] [Related]
23. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
Middleton ET; Steel SA; Aye M; Doherty SM
J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
[TBL] [Abstract][Full Text] [Related]
24. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
25. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
26. Changes in cortical microarchitecture are independent of areal bone mineral density in patients with fragility fractures.
Mussawy H; Ferrari G; Schmidt FN; Schmidt T; Rolvien T; Hischke S; Rüther W; Amling M
Injury; 2017 Nov; 48(11):2461-2465. PubMed ID: 28882378
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive therapy in osteoporosis using a single drug: from ADFR to strontium ranelate.
Manette C; Collette J; Sarlet N; Tancredi A; Zegels B; Reginster JY
Curr Med Chem; 2006; 13(13):1585-90. PubMed ID: 16787205
[TBL] [Abstract][Full Text] [Related]
28. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women.
Rolland Y; Abellan Van Kan G; Gillette-Guyonnet S; Roux C; Boonen S; Vellas B
Bone; 2011 Feb; 48(2):332-8. PubMed ID: 20817053
[TBL] [Abstract][Full Text] [Related]
29. Increased bone strength is associated with improved bone microarchitecture in intact female rats treated with strontium ranelate: a finite element analysis study.
Boyd SK; Szabo E; Ammann P
Bone; 2011 May; 48(5):1109-16. PubMed ID: 21276882
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Recker RR; Marin F; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Farrerons J; Sanz B; Oertel H; Stepan J
J Bone Miner Res; 2009 Aug; 24(8):1358-68. PubMed ID: 19338452
[TBL] [Abstract][Full Text] [Related]
31. Strontium ranelate in osteoporosis and beyond: identifying molecular targets in bone cell biology.
Marie PJ
Mol Interv; 2010 Oct; 10(5):305-12. PubMed ID: 21045244
[TBL] [Abstract][Full Text] [Related]
32. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate.
Arlot ME; Jiang Y; Genant HK; Zhao J; Burt-Pichat B; Roux JP; Delmas PD; Meunier PJ
J Bone Miner Res; 2008 Feb; 23(2):215-22. PubMed ID: 17922612
[TBL] [Abstract][Full Text] [Related]
33. Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling.
Winzenrieth R; Humbert L; Di Gregorio S; Bonel E; García M; Del Rio L
Osteoporos Int; 2018 Oct; 29(10):2323-2333. PubMed ID: 29974136
[TBL] [Abstract][Full Text] [Related]
34. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
35. Strontium as therapy for osteoporosis.
Marie PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Bone Quality in Osteoporosis Treatment with Bone Anabolic Agents: Really Something New?
Ulivieri FM; Caudarella R; Camisasca M; Cabrini DM; Merli I; Messina C; Piodi LP
Curr Rheumatol Rev; 2018 Apr; 14(1):53-61. PubMed ID: 27908253
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
[TBL] [Abstract][Full Text] [Related]
38. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
39. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Macdonald HM; Nishiyama KK; Hanley DA; Boyd SK
Osteoporos Int; 2011 Jan; 22(1):357-62. PubMed ID: 20458576
[TBL] [Abstract][Full Text] [Related]
40. The use of combination therapy in the treatment of postmenopausal osteoporosis.
Compston J
Endocrine; 2012 Feb; 41(1):11-8. PubMed ID: 22038453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
